RegeneRx has join hands with the U.S. Army Medical Research Institute of Chemical Defense and Gabriel Sosne, MD, associate professor of ophthalmology at Wayne State University, to evaluate the ability of its eye drop formulation of Tß4 for preventing or reducing damage to the eye caused by exposure to chemical agents.
Over the next year, the partnership plans to conduct a series of research experiments with the drug, called, RGN-259.
RegeneRx is developing the the drug called RGN-259, for treating ophthalmic wounds and related disorders. The drug already shows success in treating non-healing eye ulcers of keratitis patients.
RGN-259 was applied to corneal ulcers that had not healed for at least 6 weeks and for up to several months. By treatment day 28, eye ulcers had either healed completely or demonstrated significant improvement in all four patients, according to the release.
Thirty days after the treatment, ulcers had completely healed or remained healed; those that had demonstrated significant improvement continued to improve after treatment had ended.
RGN-259 was well-tolerated with no drug-related adverse events.
J.J. Finkelstein, president and chief executive officer of RegeneRx, believes that their technology will successfully pass the testing of US army. RegeneRx is prepared to assist in any way possible to support efforts to protect the eyes of military personnel and citizens from exposure to debilitating or life-threatening chemical agents.
RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively.
These product candidates are based on TB4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to its products and has sponsored four Phase II dermal and ophthalmic clinical trials and a Phase I parenteral (injectable) clinical trial supporting systemic delivery of RGN-352 for acute cardiovascular indications.